Kyverna Therapeutics/$KYTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Ticker

$KYTX
Sector
Primary listing

Employees

129

KYTX Metrics

BasicAdvanced
$309M
-
-$3.67
-
-

What the Analysts think about KYTX

Analyst ratings (Buy, Hold, Sell) for Kyverna Therapeutics stock.

Bulls say / Bears say

Completed enrollment for the registrational Phase 2 KYSA-8 trial in stiff-person syndrome in Q2 2025, setting the stage for topline data and its first BLA filing in H1 2026. (GlobeNewswire)
Maintained a strong liquidity position with $211.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which extends operating runway into 2027. (GlobeNewswire)
Secured FDA alignment for a registrational Phase 3 KYV-101 trial in myasthenia gravis, aiming to launch the cohort by year-end 2025 and share interim Phase 2 data in Q4 2025. (GlobeNewswire)
Reported a net loss of $42.1 million in Q2 2025, up 46% year-over-year, highlighting increased cash burn and widening losses. (StockTitan)
Operating cash used rose to $76.9 million in the first half of 2025, compared to $49.7 million a year ago, accelerating depletion of liquidity reserves. (StockTitan)
Faces future obligations that could reach up to $64.5 million in milestone and royalty payments under existing collaboration agreements, potentially putting pressure on finances if they come due. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 10 Oct 2025.

KYTX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

KYTX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KYTX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Kyverna Therapeutics stock | $KYTX Share Price | Lightyear